Newsroom

Sorted by: Latest
-

Orano: Résultats semestriels 2026 en ligne avec les perspectives annuelles malgré des arrêts de production conjoncturels

PARIS--(BUSINESS WIRE)--Regulatory News: Orano: Activité globalement stable avec des situations contrastées par secteur, EBITDA pénalisé par des arrêts de production Chiffre d’affaires de 2 696 M€, en légère progression de + 2,1 % (p.c.c.), marqué par une bonne performance du secteur Aval et un écoulement moins favorable du carnet de commandes des secteurs Mines et Amont entre les deux périodes. EBITDA en baisse à 595 M€ (contre 727 M€ au 1er semestre 2025) compte tenu d’arrêts de production da...
-

Orano: 2026 Half-Year Results in Line With Annual Outlook Despite Circumstantial Production Stoppages

PARIS--(BUSINESS WIRE)--Orano: 2026 half-year results in line with annual outlook despite circumstantial production stoppages...
-

Renesas Reports Financial Results for the Second Quarter Ended June 30, 2026

TOKYO--(BUSINESS WIRE)--Renesas announced consolidated financial results in accordance with IFRS for the three and six months ended June 30, 2026....
-

Renesas to Phase Out Production at Takasaki Factory; Maintain and Strengthen R&D Functions

TOKYO--(BUSINESS WIRE)--Renesas will gradually scale down and end manufacturing operations at the Takasaki Factory over the next 2 to 3 years while maintaining R&D functions....
-

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

ROTKREUZ, Switzerland--(BUSINESS WIRE)--Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults w...
-

Renesas Announces Consolidated Forecasts

TOKYO--(BUSINESS WIRE)--Renesas today announced the consolidated financial forecasts for the nine months ending September 30, 2026....
-

Notice Concerning the Recording of Finance Income

TOKYO--(BUSINESS WIRE)--Renesas today announced the recording of finance income in the three months ended June 30, 2026 (April 1, 2026 to June 30, 2026)....
-

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

TOKYO--(BUSINESS WIRE)--Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZenec...
-

BE CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Bloom Energy Corporation

LOS ANGELES--(BUSINESS WIRE)--BE CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Bloom Energy Corporation...
-

Deutsche Bank AG UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  City of Stockholm Issue of SEK 600,000,000.00 Floating Rate Notes due May 2029 Series EMTN100 Tranche 1 MTN ISSUE NAME. Our Ref. MQ5772 ISIN Code. XS2758113190 TOTAL INTEREST AMT. CURRENCY CODE. SEK DAY BASIS. Actual/360 (A004) NUM OF DAYS. 91 INTEREST RATE. 2.784 PCT VALUE DATE. 02/11/2026 INTEREST PERIOD. 03/08/2026 TO 02/11/2026 SEK 4,222,400 POOL FACTOR. N/A...